CLL Biobank: Mechansims in drug resistance in chronic lymphocytic leukemia, Canada

Certification Status: Approved
Registration Status: Completed

Objective: Chronic lymphocytic leukemia (CLL) remain an incurable leukemia even with targeted therapies extending remissions and overall survival in CLL patients. Eventually the CLL cells become resistant to these targeted therapies requiring new approaches to treat this disease. In this study, we will collect blood samples from CLL patients before they receive treatment, during treatment and at time of relapse. We will evaluate mechanisms of drug resistance in the cells such as reactive oxygen species levels, autophagy flux and Bcl-2 family members following targeted treatments with Ibrutinib or venetoclax. This will give insight into the mechanism of drug resistance and strategies to overcome this resistance.

Registered Biobank Name CLL Biobank: Mechansims in drug resistance in chronic lymphocytic leukemia
Biobank Leader Spencer B Gibson
Country Canada
Email for biobank inquiries sgibson2@ualberta.ca
Principal Investigator Spencer Gibson
User Type
  • Mono: A biobank that supports a specific research project, may have few staff members, a small-scale accrual scope with little to no initial intention of releasing or distributing biospecimens to secondary parties
  • Oligo: A biobank that supports several research groups or clinical trials, may or may not be designed to release biospecimens outside their collaborative group
  • Poly: A biobank that has generally a larger accrual scope, resources, and multiple users outside the biobank proper
 Oligo - Collection aimed at supporting several research projects, a research group or a research consortium
Biospecimen Collected: